Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

Click for more information

0.00%

20.5¢ raptor resources limited

rap chart, page-3474

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 3474 Last

Share
Profile

Follow
Dhm

2,422 Posts.

3567

27/07/20

18:02

Post #: 46102109
Share

Originally posted by showie: ↑

Just had a response to my enquiry:

Dear XXXXXXX,

We are writing in response to your recent enquiry, submitted to the Department of Health's AskMBS advice service on 9/07/2020.

Your enquiry has been considered and the following response is provided:The COVID-19 telehealth items are intended to substitute directly for standard attendance items and are subject to the same requirements. The personal attendance of the medical practitioner upon the patient is necessary before a ‘consultation’ may be regarded as a professional attendance. For the purposes of the COVID-19 telehealth items, the interaction between doctor and patient by video or telephone is regarded as personal attendance. In itemising an attendance covered by an MBS item which refers to a period of time, only that time during which a patient is receiving active attention should be counted.

A patient undertaking ‘remote respiratory smart-phone testing’ prior to their appointment with the doctor would not be eligible for a Medicare benefit as no personal attendance has occurred. No other MBS item would be appropriate for this task.

In relation to the time taken in recording details of the service, only clinical details recorded at the time of the attendance upon the patient count towards the time of attendance. It does not include information added at a later time, such as completing progress notes, speaking with nursing staff and/or patients’ families away from the patient. This also applies to information gathered or recorded prior to the attendance service.

Under MBS claiming arrangements, it is the responsibility of the health care professional providing the service to ensure that all of the requirements of the relevant MBS item, as detailed in the item descriptor and associated explanatory notes, have been met and the service provided is clinically relevant. A medical service is considered clinically relevant if it is generally accepted in the medical profession as necessary for the appropriate treatment of the patient.

It is the treating practitioner’s responsibility to consider the clinical circumstances of any services rendered and to determine the appropriate MBS item(s) to claim, if any. They should also exercise care to ensure that their conduct in relation to rendering the services cannot be characterised as inappropriate practice i.e. practice that a practitioner’s peers could reasonably conclude was unacceptable to the general body of their profession.

The full MBS item descriptors and associated explanatory notes can be searched for and viewed at www.mbsonline.gov.au

New temporary MBS telehealth and telephone consultation items have been made available to help reduce the risk of community transmission of COVID-19 and provide protection for patients and health care providers. The new items are available to all Medicare-eligible Australians until 30 September 2020 (when the arrangements will be reviewed). The list of telehealth services has continued to expand since 13 March with items now available to GPs, other medical practitioners, specialists and consultant physicians (including psychiatrists), nurse practitioners, participating midwives, allied health professionals and allied mental health providers. There are also new pathology items for COVID-19 testing and new bulk billing items for COVID-19 patients and those at risk of the virus.

Please see the link below to the most recent news and a list of the COVID-19 MBS items, noting that this is an evolving situation and it is possible that some of this information could change in response to circumstances.

Please refer to MBS Online at: www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/news
Should you require further clarification please contact [email protected],

Expand

Hi @showie I really hope you don't mind, but the response by the MBS really got under my skin and I have drafted a response. We need a more educated MBS:

Hello,
I am writing regarding your recent email response to a peer of mine on whether the remote diagnostic assessment via ResAppDx (which is TGA approved as a Class 2a diagnostic tool) should be rebateable as telehealth appointments are. The decision made by yourselves was "no, and there is no MBS item that would be appropriate for this 'task'."

The respondent in your email stated: "Under MBS claiming arrangements, it is the responsibility of the health care professional providing the service to ensure that all of the requirements of the relevant MBS item, as detailed in the item descriptor and associated explanatory notes, have been met and the service provided is clinically relevant. A medical service is considered clinically relevant if it is generally accepted in the medical profession as necessary for the appropriate treatment of the patient." The highlighted part of your response is important to my point as any telehealth respiratory consultation needs some form of diagnostic tool, as the doctor cannot use a stethoscope. Hence, the importance of ResAppDx as it acts remotely as the doctor's stethoscope.

With respect, I ask that you reconsider this response as I don't believe you fully understand the significance of this technology, and the amount of time and associated testing (x-rays, sputum) to confirm a diagnosis that would be needed if ResAppDx didn't exist. This tech is accurate, fast and reliable (as per TGA approval) and the patient would commence treatment virtually immediately. ResAppDx has been adopted by Coviu (HealthDirect and HealthEngine) and Phenix Health in Australia, and a significant number of UK hospitals are testing the cost effectiveness of the tech which may lead to widespread adaption of it. ResApp is also CE Marked as a Class 2a diagnostic tool.

May I also lead you to the ResApp Health website which gives further explanation as to the groundbreaking nature and global potential of this product.
https://www.resapphealth.com.au/

RAP Price at posting: 13.5¢ Sentiment: Buy Disclosure: Held
19 Upvote

4 Great analysis

Reply

Top Stories

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Trump is President Again: What Does This Mean for Crypto?

AR3

Overland drilling proves promising for Australian Rare Earths' uranium hopes

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

CPV

ClearVue inks deal with UK heated glass player to combine solar tech with its offering

There are more pages in this discussion • 1,168 more messages in this thread...

First 3474 Last

Add RAP (ASX) to my watchlist